EOLS Q4 2023 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$61M+39.8% YoY

Gross Profit

$39M63.6% margin

Operating Income

-$9M-14.2% margin

Net Income

-$12M-19.4% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+22.0%

Cash Flow

Operating Cash Flow

$813,000

Free Cash Flow

$452,000

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$189M

Total Liabilities

$210M

Stockholders' Equity

-$21M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$61M	$44M	+39.8%
Gross Profit	$39M	$30M	+28.1%
Operating Income	-$9M	-$11M	+18.8%
Net Income	-$12M	-$13M	+10.1%

Revenue Segments

Product

$61M99%

Service

$328,0001%